查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015152

神經血管和神經系統醫療設備市場：按產品、適應症、技術、最終用戶和分銷管道分類－2026-2032年全球市場預測

Neurovascular Neurology Devices Market by Product, Indication, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年神經血管和神經醫療設備市場價值為45.8億美元，預計到2026年將成長至47.8億美元，複合年成長率為5.46%，到2032年將達到66.5億美元。

主要市場統計數據
基準年 2025 45.8億美元
預計年份：2026年 47.8億美元
預測年份 2032 66.5億美元
複合年成長率 (%) 5.46%

策略性地引入神經血管醫療設備，重點關注臨床緊迫性、多學科護理路徑以及影響治療結果的技術趨勢。

神經血管器材領域正處於技術創新、臨床緊迫性和不斷發展的診療路徑的交匯點，因此需要為醫療保健、投資和監管領域的相關人員提供清晰、以臨床為導向的介紹。本文概述了當前形勢，重點介紹了微創治療和影像技術的進步如何改變了急性中風治療、動脈瘤管理和血管畸形治療。臨床醫生越來越依賴兼具精密機械性能和更佳輸送能力的精準器械，而影像解析度和手術引導系統的同步改進也推動了這一趨勢。

設備工程、影像分析和醫療保健服務系統的重新設計如何改變神經血管治療的臨床部署、採購和創新途徑。

神經血管介入治療的現狀正經歷著一場變革，這主要得益於器材工程、數位診斷和醫療系統組織等方面的整合發展。在器材層面，純粹的機械解決方案正加速整合式平台轉型。新型血流滲透性結構和生物活性表面處理技術體現了在最大限度減少輔助手術的同時，實現動脈瘤持續閉塞的理念；而取栓器和抽吸裝置設計的創新則優先考慮血栓的安全捕獲和減少內皮損傷。同時，影像和分析技術的進步使得病變表徵和手術規劃更加精準，加速了針對特定解剖和病理亞型的器械的研發。

評估美國新關稅對整個醫療設備產品組合的採購、製造地轉移和創新資金籌措的累積營運和策略影響。

美國將於2025年開始加徵關稅，這將為參與全球神經血管器械生產和分銷的相關人員帶來新的挑戰，其累積影響將波及採購、製造以及研發投資決策。關稅帶來的成本壓力在跨境供應鏈中集中的零件和原料上最為顯著，例如特殊合金、導管軸和滲透性標記。隨著這些投入成本的上升，製造商被迫做出策略性選擇：自行承擔成本、重新分配利潤，或將價格上漲轉嫁給經銷商和醫療系統。

將產品設計、臨床應用、交付技術、醫療保健環境和分銷策略聯繫起來的細分市場洞察，以推動產品採用和差異化。

精細的細分分析揭示了臨床需求、器材機制和分銷管道動態如何相互作用，從而影響產品上市模式和商業性優先事項。在產品類型中，球囊血管成形術導管依其球囊技術可分為順應性球囊和非順應性球囊。順應性球囊適用於細部的血管重塑，而非順應性球囊則適用於需要精確擴張管腔的情況。栓塞彈簧圈分為裸彈簧圈、塗層彈簧圈和水凝膠彈簧圈，每種亞型在即時閉塞、組織整合和長期穩定性之間各有優劣，影響臨床醫生的選擇。血流導向裝置分為可生物分解型和永久性型。可生物分解型血流導向裝置更受那些希望在不承受終身植入負擔的情況下進行血管修復的臨床醫生青睞，而永久性血流導向裝置仍然是某些複雜動脈瘤形態的標準選擇。神經血管支架採用球囊擴張型或自擴張式結構，選擇取決於所需的徑向支撐力、血管曲率和輸送限制。血栓摘取支架，其特點在於血栓捕獲機制、輸送能力以及與抽吸輔助裝置的兼容性。

美洲、歐洲、中東和非洲以及亞太地區的臨床基礎設施的區域趨勢和差異影響著監管路徑、報銷重點和部署模式。

區域趨勢反映了監管、醫療服務體系和支付方行為的差異，這些差異影響神經血管器械領域的臨床實踐和商業策略。在美洲，完善的卒中治療體系和一體化的醫院網路促進了先進血栓切除術和血流導向技術的快速應用。此外，高水準的醫療中心和大量的手術量使得強化訓練計畫得以開展，從而有助於收集真實世界的臨床證據，並進一步加速器械的推廣應用。區域採購環境通常強調證明綜合治療的經濟效益和價值，促使器械供應商將臨床數據與健康經濟學論點結合。

透過運用競爭定位和夥伴關係策略，我們將臨床證據、訓練計畫和供應鏈韌性結合，以確保在介入醫師中保持持續的偏好。

神經血管器材領域的競爭動態取決於規模優勢與敏捷創新之間的平衡。大型醫療設備公司利用其廣泛的臨床試驗網路、豐富的監管合規經驗和一體化的服務交付體系，與患者數量龐大的醫療機構保持長期合作關係。這些成熟企業通常會投資於互補技術、培訓機構和長期的上市後監測，以鞏固臨床認可並向支付方證明其價值。同時，敏捷的新興企業正在推動差異化技術的研發，例如突破性的生物可吸收血流導引裝置、先進的聚合物塗層線圈和新一代吸痰導管。這些技術一旦擁有令人信服的臨床數據支持，就能迅速贏得臨床關注。

為領導者提供一系列切實可行的建議，以協調臨床證據、供應鏈韌性、商業化模式和支付方參與，從而實現永續成長。

產業領導者應採取多管齊下的策略，將產品創新與嚴格的商業化、與臨床機構的合作以及供應鏈韌性相結合。首先，他們應優先考慮以患者為中心的臨床項目，這些項目能夠產生有意義的終點指標和可操作的證據，從而引起臨床醫生和支付方的共鳴。註冊研究和可操作的臨床試驗是隨機試驗的補充，有助於更快地獲得更具普遍適用性的見解。其次，他們應重新設計供應鏈策略，透過認證替代供應商、探索關鍵零件的近岸外包以及建立庫存緩衝來降低關稅和零件集中度風險，從而確保產品按計劃上市。

檢驗臨床和商業性發現，該研究結合了對臨床醫生、專家小組的訪談和系統的文獻整合。

本調查方法結合了嚴謹的一手資料和二手資料研究，以確保研究結果對相關人員具有相關性、實用性和意義。一手資料研究包括對介入醫師、醫院採購經理和醫療設備公司高階主管進行結構化訪談，以了解他們對器械選擇、手術偏好和推廣障礙的實際觀點。除訪談外，還組織了由中風和血管神經外科專家組成的專題研討會，以檢驗臨床假設並解讀手術趨勢。二手資料研究系統地回顧了同行評審文章、臨床試驗註冊資料、監管申報文件和醫療設備技術文獻，以交叉檢驗研究結果並闡明創新發展軌跡。

簡明扼要的總結強調，需要協調創新、證據產生和商業性實施，才能將醫療設備的進步與改善病患預後連結起來。

總之，神經血管和神經系統領域的醫療設備市場呈現出快速的技術進步、不斷演變的醫療服務模式以及對價值鏈中價值和韌性的日益重視等特徵。儘管醫療設備設計和影像技術的進步顯著提升了手術能力，但可靠的臨床證據、合理的報銷策略以及貫穿整個醫療體系的完善營運框架對於永續應用至關重要。政策變化和貿易趨勢帶來了新的限制因素，因此需要透過採購多元化和策略夥伴關係等積極主動的風險緩解措施來應對。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：神經血管與神經系統醫療設備市場：依產品分類

  • 球囊血管成形術導管
    • 符合規範的氣球
    • 不合規的氣球
  • 栓塞線圈
    • 裸露線圈
    • 塗層線圈
    • 水凝膠線圈
  • 分流器
    • 可生物分解的導流板
    • 永久性分流器
  • 神經血管支架
    • 球囊擴張型支架
    • 自動擴張型支架
  • 血栓摘取支架系統
    • 單人紙牌
    • 特雷沃

第9章：神經血管與神經系統醫療設備市場：依適應症分類

  • 動脈瘤閉塞
    • 梭形動脈瘤
    • 囊狀動脈瘤
  • 動靜脈畸形
  • 出血性中風
  • 缺血性中風
    • 循環系統前中風
    • 循環後中風

第10章：神經血管與神經系統醫療設備市場：依技術分類

  • 化學溶栓療法
  • 血液旁路
  • 機械血栓切除術
    • 吸痰管
    • 血栓摘取支架

第11章：神經血管與神經系統醫療設備市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章：神經血管與神經系統醫療設備市場：依分銷管道分類

  • 直銷
  • 銷售代理

第13章：神經血管與神經系統醫療設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：神經血管與神經系統醫療設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：神經血管和神經系統醫療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國神經血管與神經醫療設備市場

第17章：中國神經血管與神經醫療設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Acandis GmbH
  • Asahi Intecc Co., Ltd.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cerenovus, LLC
  • Johnson & Johnson
  • Medtronic plc
  • MicroPort Scientific Corporation
  • MicroVention, Inc.
  • Penumbra, Inc.
  • Stryker Corporation
  • Terumo Corporation
Product Code: MRR-036C5CF3B4E4

The Neurovascular Neurology Devices Market was valued at USD 4.58 billion in 2025 and is projected to grow to USD 4.78 billion in 2026, with a CAGR of 5.46%, reaching USD 6.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.58 billion
Estimated Year [2026] USD 4.78 billion
Forecast Year [2032] USD 6.65 billion
CAGR (%) 5.46%

A strategic introduction to neurovascular devices emphasizing clinical urgency, multidisciplinary care pathways, and technological trends shaping procedural outcomes

Neurovascular neurology devices are at the intersection of technological innovation, clinical urgency, and evolving care pathways, demanding a clear, clinically informed introduction for stakeholders across healthcare, investment, and regulatory spheres. This introduction frames the current landscape by highlighting how advances in minimally invasive therapies and imaging have reshaped acute stroke care, aneurysm management, and the treatment of vascular malformations. Clinicians increasingly rely on precision devices that integrate refined mechanical properties with improved deliverability, and this trend is supported by parallel enhancements in imaging resolution and procedural guidance systems.

The clinical context is defined by persistently high morbidity and mortality associated with cerebrovascular events, which creates sustained pressure to improve time-to-treatment, procedural success rates, and long-term neurological outcomes. In response, device developers have focused on reliability of deployment, reduced intraprocedural complications, and materials science innovations that modulate thrombogenicity and healing responses. At the same time, health systems are realigning care networks to prioritize rapid triage, centralized thrombectomy-capable centers, and expanded roles for ambulatory procedural settings where appropriate.

Regulatory and reimbursement dynamics remain central to adoption trajectories, with approvals increasingly tied to robust clinical endpoints and post-market surveillance commitments. Collaboration among interventional neuroradiologists, neurosurgeons, and stroke neurologists is deepening, and this multidisciplinary engagement is accelerating iterative device improvements and real-world evidence generation. Taken together, these forces situate neurovascular devices as a strategic priority for organizations seeking durable impact on patient outcomes and long-term value creation.

How device engineering, imaging analytics, and care delivery redesign are together reshaping clinical adoption, procurement, and innovation pathways in neurovascular care

The landscape of neurovascular interventions is undergoing transformative shifts driven by convergent advances in device engineering, digital diagnostics, and health-system organization. At the device level, a move from purely mechanical solutions toward integrated platforms has accelerated: newer flow diversion constructs and bioactive surface treatments reflect an emphasis on durable aneurysm occlusion with fewer adjunctive procedures, while innovations in retriever and aspiration designs prioritize clot engagement and reduced endothelial trauma. Concurrently, imaging and analytics enhancements are enabling more accurate lesion characterization and procedural planning, which in turn supports device iteration that targets specific anatomical and pathological subtypes.

Operationally, there is an unmistakable shift toward decentralizing certain procedures to low-acuity settings where patient selection and streamlined protocols permit safe, cost-efficient interventions. This hybridization of care delivery models is being enabled by device designs optimized for outpatient use and simplified inventory management. In addition, clinical trial designs are evolving to emphasize adaptive protocols and real-world evidence, allowing faster translation of promising technologies while preserving methodological rigor.

On the macro front, supply chain resilience and regulatory harmonization are influencing product roadmaps and market entry strategies. Companies are investing in localized manufacturing, strategic partnerships, and value-based contracting to navigate reimbursement pressures and procurement rationalization. Taken together, these transformative shifts are not incremental; they reshape competitive positioning, clinician decision-making, and the timelines for broad clinical adoption.

Evaluating the cumulative operational and strategic consequences of new U.S. tariffs on procurement, manufacturing relocation, and innovation funding across device portfolios

The imposition of United States tariffs in 2025 has introduced a new layer of complexity for stakeholders engaged in the global production and distribution of neurovascular devices, with cumulative effects that extend across procurement, manufacturing, and R&D investment decisions. Tariff-driven cost pressure is most immediately apparent in components and raw materials that are concentrated in cross-border supply chains, including specialty alloys, catheter shafts, and radio-opaque markers. When these inputs become more expensive, manufacturers face strategic choices about absorbing costs, reallocating margins, or passing increases downstream to distributors and health systems.

Consequently, procurement organizations and hospital systems are reassessing supplier diversification and contract terms, accelerating efforts to secure price predictability through longer-term agreements or local sourcing arrangements. For device companies, the tariffs incentivize supply chain reconfiguration: nearshoring production, qualifying alternate suppliers, and increasing vertical integration where feasible. These responses can mitigate exposure over time but often require upfront capital and extended qualification timelines that compete with R&D allocations.

Smaller innovators are particularly vulnerable, as elevated import costs may constrain their ability to scale clinical trials and commercial launches without strategic partnerships. At the same time, larger incumbents with diversified manufacturing footprints can leverage scale to normalize pricing changes, albeit at the cost of redirecting resources that might otherwise fund product development or market expansion. In aggregate, the tariffs catalyze a re-evaluation of the cost-to-serve for international product portfolios, reinforcing the importance of resilience planning, scenario modeling, and proactive dialogue with payers to preserve access for clinicians and patients.

Segment-level insights connecting product design, clinical indications, delivery technologies, care settings, and distribution strategies to drive adoption and differentiation

A nuanced segmentation analysis reveals how clinical need, device mechanics, and channel dynamics interact to shape adoption patterns and commercial priorities. Within product categories, balloon angioplasty catheters are differentiated by compliant versus noncompliant balloon technologies, where compliant balloons are preferred for delicate vessel remodeling and noncompliant variants are favored when precise luminal expansion is required. Embolic coils vary across bare coils, coated coils, and hydrogel coils, and each subtype presents trade-offs between immediate occlusion, tissue integration, and long-term stability that inform clinician selection. Flow diverters divide into biodegradable and permanent devices; biodegradable flow diverters appeal to clinicians seeking vessel restoration without lifelong implant burden, while permanent flow diverters remain the default for certain complex aneurysm morphologies. Neurovascular stents are produced as balloon-expandable or self-expanding constructs, with choice contingent on radial force needs, vessel tortuosity, and delivery constraints. Stent retriever systems, exemplified by Solitaire and Trevo designs, are distinguished by clot engagement mechanics, deliverability profiles, and compatibility with aspiration adjuncts.

When analyzed by indication, aneurysm occlusion strategies must account for fusiform versus saccular anatomy, with device selection influenced by neck morphology and parent vessel involvement. Treatments for arteriovenous malformations require a different procedural mindset focused on nidus access and embolic control, while hemorrhagic stroke interventions prioritize hemostatic stabilization and prevention of rebleeding. Ischemic stroke management bifurcates into anterior circulation and posterior circulation strokes, where anatomical access, collateral circulation, and time sensitivity dictate device choice and procedural strategy.

Technological segmentation highlights distinctions between chemical thrombolysis, flow diversion, and mechanical thrombectomy. Mechanical thrombectomy further subdivides into aspiration catheter strategies and stent retrievers, each offering complementary strengths in clot retrieval efficiency and compatibility with adjunctive devices. End user segmentation shows divergent needs among ambulatory surgical centers, hospitals, and specialty clinics: ambulatory settings require devices optimized for streamlined turnover and lower complexity cases, hospitals maintain broad inventories for high-acuity procedures, and specialty clinics emphasize devices that support repeatable interventions and specialized follow-up care. Distribution channel dynamics between direct sales and distributors influence training, service levels, and pricing transparency, with direct sales enabling tighter clinical support and distributors offering broader geographic reach and inventory buffering. Collectively, these segmentation lenses illuminate how product design, clinical indication, technology choice, care setting, and channel strategy must be aligned to realize both clinical impact and commercial success.

Regional dynamics and clinical infrastructure differences that influence regulatory pathways, reimbursement priorities, and adoption models across Americas, EMEA, and Asia-Pacific

Regional dynamics shape both clinical practice and commercial strategy across the neurovascular device landscape, reflecting differences in regulation, provider infrastructure, and payer behavior. In the Americas, robust stroke systems of care and consolidated hospital networks support rapid adoption of advanced thrombectomy and flow diversion technologies; centers of excellence and high procedural volumes enable intensive training programs and foster real-world evidence collection that further accelerates device uptake. The purchasing environment in this region often emphasizes bundled care economics and value demonstration, prompting device sponsors to couple clinical data with health-economic narratives.

Europe, the Middle East & Africa exhibits heterogeneity driven by national regulatory pathways, variable reimbursement policies, and disparate access to interventionists. In Western Europe, centralized health technology assessment processes and strong clinical registries create a pathway for adoption that prioritizes long-term outcomes and cost-effectiveness. In parts of the Middle East and Africa, investment in neurointerventional capacity is emerging, but adoption is constrained by workforce distribution and infrastructure gaps, leading to targeted opportunities for scalable training and service models.

Asia-Pacific presents a large and diverse opportunity set characterized by rapid hospital expansion, increased investment in tertiary stroke centers, and local manufacturing growth. Regulatory timelines vary significantly across jurisdictions, and market entry strategies often require partnerships with regional distributors or local manufacturers. Furthermore, demographic trends and growing awareness of stroke risk factors are driving demand for both acute intervention devices and chronic management solutions, while price sensitivity in certain markets compels tailored product portfolios and flexible commercial arrangements. Across all regions, harmonizing clinical evidence generation and post-market surveillance practices remains critical to sustaining adoption and informing iterative device improvements.

Competitive positioning and partnership strategies that combine clinical evidence, training programs, and supply chain resilience to secure lasting preference among interventionists

Competitive dynamics across the neurovascular devices arena are defined by a balance between scale-driven capabilities and nimble innovation. Leading medtech firms leverage extensive clinical trial networks, broad regulatory experience, and integrated service offerings to maintain durable relationships with high-volume centers. These incumbents often invest in complementary technologies, training academies, and long-term post-market studies to entrench clinical preference and demonstrate value to payers. At the same time, agile emerging companies are advancing differentiated technologies-such as novel bioresorbable flow diverters, advanced polymer-coated coils, and next-generation aspiration catheters-that can rapidly capture clinical interest when supported by compelling procedural data.

Partnerships and strategic alliances are increasingly common, enabling smaller innovators to access commercialization expertise and scale while allowing larger firms to augment their pipelines with targeted capabilities. Mergers and acquisitions continue to be a key mechanism for acquiring novel intellectual property and expanding geographic reach, although transactions are subject to careful scrutiny given regulatory complexity and the need to integrate clinical education efforts.

Service and training models are also a point of differentiation; companies that provide hands-on proctoring, hybrid simulation programs, and post-procedural analytics strengthen clinician adoption and reduce the learning curve for complex devices. Finally, companies that proactively address supply chain resilience, cost transparency, and value demonstration position themselves favorably with health systems navigating budgetary and procurement constraints. Collectively, these strategic behaviors define a competitive environment where clinical evidence, support infrastructure, and supply-chain reliability are as consequential as device performance.

A pragmatic set of high-impact recommendations for leaders to align clinical evidence, supply chain resilience, commercialization models, and payer engagement for durable growth

Industry leaders should adopt a multi-pronged strategy that aligns product innovation with commercialization rigor, clinical engagement, and supply chain resilience. First, prioritize clinical programs that generate meaningful, patient-centric endpoints and pragmatic evidence that resonates with clinicians and payers; registries and pragmatic trials can complement randomized studies and facilitate faster, generalizable insights. Second, redesign supply chain strategies to mitigate tariff exposure and component concentration risks by qualifying alternate suppliers, considering nearshoring for critical components, and establishing inventory buffers that preserve launch timelines.

Third, tailor commercial models to regional contexts by combining direct sales in high-volume centers with distributor partnerships in markets where breadth of coverage and local relationships are paramount. Fourth, invest in clinician training infrastructures that include simulation, proctoring, and digital decision support to shorten adoption curves and reduce procedural variability. Fifth, engage payers early with comprehensive value dossiers that articulate both clinical outcomes and health economic impact; performance-based contracting and outcome guarantees can be considered where alignment is feasible.

Finally, embed digital tools that enhance procedural planning, follow-up, and device performance monitoring to create a differentiated service layer that supports premium positioning. By executing on these interconnected priorities, industry leaders can accelerate safe adoption, manage cost pressures, and sustain investment in next-generation technologies.

A transparent mixed-methods research approach combining clinician interviews, expert panels, and systematic literature synthesis to validate clinical and commercial insights

The underlying research methodology combines rigorous primary and secondary approaches to ensure validity, relevance, and practical utility for stakeholders. Primary research included structured interviews with interventionalists, hospital procurement leaders, and device executives to capture frontline perspectives on device selection, procedural preferences, and adoption barriers. These interviews were complemented by expert panel discussions with clinicians specializing in stroke and vascular neurosurgery to validate clinical assumptions and interpret procedural trends. Secondary research involved systematic review of peer-reviewed publications, clinical trial registries, regulatory filings, and technical device literature to triangulate findings and contextualize innovation trajectories.

Data synthesis relied on cross-validation of qualitative insights with objective indicators such as device approval histories, guideline updates, and published procedural outcomes. Where appropriate, scenario analysis was applied to assess sensitivity to policy changes and supply chain disruptions. Quality control processes included independent editorial review, clinical advisor validation, and methodological documentation that outlines inclusion criteria, interview protocols, and limitations. Transparency about assumptions and the sources of evidence underpins the confidence in the insights presented, while acknowledging that clinical practice and policy environments continue to evolve and warrant ongoing monitoring.

A concise synthesis emphasizing the imperative to align innovation, evidence generation, and commercial execution to translate device advances into improved patient outcomes

In conclusion, the neurovascular neurology device environment is characterized by rapid technological progress, evolving care delivery models, and intensified attention to value and resilience in supply chains. Advances in device design and imaging have materially improved procedural capabilities, but sustainable adoption depends on robust clinical evidence, sensible reimbursement strategies, and operational readiness across healthcare systems. Policy shifts and trade dynamics have introduced new constraints that require proactive mitigation through diversified sourcing and strategic partnerships.

Future success will favor organizations that integrate clinical innovation with disciplined commercialization, invest in clinician training and post-market evidence, and adopt flexible regional strategies that respect regulatory and payer heterogeneity. By aligning product development with demonstrable outcomes and service-oriented propositions, stakeholders can better navigate the complex interplay of clinical need, economic pressures, and technological opportunity that defines this market. Continued attention to real-world performance data and collaborative engagement with the clinician community will be crucial to translating device innovation into improved patient outcomes at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Neurology Devices Market, by Product

  • 8.1. Balloon Angioplasty Catheters
    • 8.1.1. Compliant Balloons
    • 8.1.2. Noncompliant Balloons
  • 8.2. Embolic Coils
    • 8.2.1. Bare Coils
    • 8.2.2. Coated Coils
    • 8.2.3. Hydrogel Coils
  • 8.3. Flow Diverters
    • 8.3.1. Biodegradable Flow Diverters
    • 8.3.2. Permanent Flow Diverters
  • 8.4. Neurovascular Stents
    • 8.4.1. Balloon-Expandable Stents
    • 8.4.2. Self-Expanding Stents
  • 8.5. Stent Retriever Systems
    • 8.5.1. Solitaire
    • 8.5.2. Trevo

9. Neurovascular Neurology Devices Market, by Indication

  • 9.1. Aneurysm Occlusion
    • 9.1.1. Fusiform Aneurysm
    • 9.1.2. Saccular Aneurysm
  • 9.2. Arteriovenous Malformations
  • 9.3. Hemorrhagic Stroke
  • 9.4. Ischemic Stroke
    • 9.4.1. Anterior Circulation Stroke
    • 9.4.2. Posterior Circulation Stroke

10. Neurovascular Neurology Devices Market, by Technology

  • 10.1. Chemical Thrombolysis
  • 10.2. Flow Diversion
  • 10.3. Mechanical Thrombectomy
    • 10.3.1. Aspiration Catheters
    • 10.3.2. Stent Retrievers

11. Neurovascular Neurology Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Neurovascular Neurology Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Neurovascular Neurology Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurovascular Neurology Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurovascular Neurology Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Neurovascular Neurology Devices Market

17. China Neurovascular Neurology Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acandis GmbH
  • 18.6. Asahi Intecc Co., Ltd.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Boston Scientific Corporation
  • 18.9. Cerenovus, LLC
  • 18.10. Johnson & Johnson
  • 18.11. Medtronic plc
  • 18.12. MicroPort Scientific Corporation
  • 18.13. MicroVention, Inc.
  • 18.14. Penumbra, Inc.
  • 18.15. Stryker Corporation
  • 18.16. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. G7 N